New Delhi: The central government’s Subject Expert Committee (SEC) is likely to meet on Wednesday on drugmaker Dr. Reddy’s application seeking emergency use authorisation for the Sputnik V vaccine in India. If the SEC gives a nod, Sputnik V will be India’s third vaccine after Covaxin and Covishield, News18 reported.
Dr. Reddy’s has partnered with the Sputnik V vaccine to run clinical trials in India. It had submitted the immunogenicity data after a meeting that was held on February 24.
Dr Reddy’s has partnered with Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India. The Russian vaccine has shown an efficacy of 91.6 %.
Chennai: After the tragic death of 27-year-old Tamil Nadu entrepreneur Jayesh Ram, Zoho CEO Sridhar…
Bhubaneswar: Income Tax (I-T) department officials continued their raid for the fourth day on Monday…
Kolkata: Sealdah Civil and Criminal Court on Monday sentenced Sanjay Roy to life imprisonment for the…
Kolkata: Ahead of pronouncement of the quantum of punishment, R G Kar rape-murder convict Sanjay…
Gaza: After being held for five months, Dania Hanatsheh—a Palestinian—who was released by Israel on…
Bhubaneswar: The Odisha government is all set to launch an extensive housing survey for the…
This website uses cookies.